<DOC>
	<DOCNO>NCT00020072</DOCNO>
	<brief_summary>RATIONALE : Analyzing gene present cancer cell may useful develop good method detect , predict , treat cutaneous T-cell lymphoma . PURPOSE : Clinical trial study gene present cutaneous T-cell lymphoma cell .</brief_summary>
	<brief_title>Analysis Genes Present Cutaneous T-cell Lymphoma Cells</brief_title>
	<detailed_description>OBJECTIVES : - Identify gene expression pattern malignant T cell use diagnose cutaneous T-cell lymphoma . - Determine pattern gene expression distinguish normal skin-homing T cell malignant T cell . OUTLINE : Patients stratify disease ( Sezary syndrome v mycosis fungoides ) prior treatment ( yes v ) . All patient receive physical examination , medical history take . Patients Sezary syndrome undergo leukapheresis . Patients plaque/tumor stage mycosis fungoides undergo skin biopsy involve skin . Malignant T cell blood skin isolate pattern gene expression malignant T cell compare normal skin-homing T cell healthy donor use `` gene chip '' ( Lymphochip ) . Patients follow annually 5 year . PROJECTED ACCRUAL : A total 40 patient ( 20 per disease stratum ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven mycosis fungoides 2 plaque tumor great 1 cm size OR Immunologically proven Sezary syndrome follow : Erythroderma Lymphadenopathy Tcell receptor variable beta chain clonality great 10 % total lymphocytes flow cytometry OR CD4+CD7 Tcell fraction represent great 10 % CD4+ T cell PATIENT CHARACTERISTICS : Age : 18 85 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing HIV1 HTLV1 negative No prior intravenous drug use PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 month since prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 month since prior electron beam radiotherapy Surgery : Not specify Other : At least 2 week since prior topical therapy At least 2 month since prior photopheresis At least 2 month since prior psoralen ultraviolet light ( PUVA ) ultraviolet B ( UVB ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>mycosis fungoides/Sezary syndrome</keyword>
</DOC>